Filed Pursuant to Rule 424(b)(3)
                                                     Registration No. 333-106294


PROSPECTUS SUPPLEMENT NO. 3
TO PROSPECTUS DATED OCTOBER 14, 2003

                                  $200,000,000
             2.5% CONTINGENT CONVERTIBLE SUBORDINATED NOTES DUE 2033
                                       AND
                              CLASS A COMMON STOCK
                      ISSUABLE UPON CONVERSION OF THE NOTES

                            [K-V PHARMACEUTICAL LOGO]

                           K-V PHARMACEUTICAL COMPANY
                                 ---------------

         This document supplements our prospectus dated October 14, 2003 (the
"prospectus"), relating to $200,000,000 aggregate principal amount of our 2.5%
Contingent Convertible Subordinated Notes Due 2033 (the "Notes") and the Class A
common stock issuable upon conversion of the Notes. You should read this
prospectus supplement in conjunction with the accompanying prospectus, which is
to be delivered by selling securityholders to prospective purchasers along with
this prospectus supplement and any other prospectus supplements. The information
in the following table supplements the information under the caption "Selling
Securityholders" in the prospectus by (i) substituting the information contained
in this Supplement No. 3 for the information contained in the prospectus with
respect to DBAG London, and (ii) supplementing the information contained in the
prospectus with the information contained in this Supplement No. 3 with respect
to the other securityholders listed below.



                                                   AGGREGATE                             CLASS A            CLASS A
                                                   PRINCIPAL                           COMMON STOCK          COMMON
                                                    AMOUNT            PERCENTAGE       BENEFICIALLY          STOCK
                                                 OF NOTES THAT         OF NOTES        OWNED BEFORE        REGISTERED
                    NAME                          MAY BE SOLD         OUTSTANDING     CONVERSION (1)         HEREBY
                                                                                               
DBAG London............................           25,110,000            12.555%              0             1,091,266
Deutsche Bank Securities Inc.(2).......            6,215,000             3.108%              0               270,100
KBC Financial Products USA Inc.........              250,000             0.125%              0                 0,865
                                                  ----------            ------             ---             ---------
         Subtotal......................           31,575,000            15.788%              0             1,362,231
                                                  ==========            ======             ===             =========



- ---------------

(1) Based upon the information provided to us by the selling securityholders,
    none of the current holders of the Notes beneficially owns any Class A
    common stock. The information presented assumes that any future transferee
    from any holder does not beneficially own any Class A common stock, other
    than Class A common stock into which the Notes are convertible at the
    conversion rate of 43.4594 shares per $1,000 principal amount of the Notes.

(2) Deutsche Bank Securities Inc. served as one of the managing underwriters in
    our public offering of 4,600,000 shares of Class A common stock in July
    2002, and as an initial purchaser in the private placement of the Notes.
    It received customary compensation for those services.

         Investing in the Notes and the Class A common stock issuable upon their
conversion involves certain risks. See "Risk Factors" beginning on page 7 of the
accompanying prospectus.







         Neither the securities and exchange commission nor any state securities
commission has approved or disapproved of the Notes or the Class A common stock
available upon conversion of the Notes or passed upon the adequacy or accuracy
of this prospectus supplement or the accompanying prospectus. Any representation
to the contrary is a criminal offense.

                    The date of this prospectus supplement is November 12, 2003.